Drug intelligence / Profile preview

LAU-PM-05

Development stage: Unknown
Lead developer: Vectans Pharma
Modality: Small Molecules
Administration: Topical

Overview

LAU-PM-05 is an antiviral drug candidate developed by Vectans Pharma for the treatment of herpes virus infections, including herpes labialis (cold sores). The drug utilizes the proprietary Lauriad technology, which is a muco-adhesive buccal tablet (MBT) designed to adhere to the upper gum and provide sustained release of the active ingredient, penciclovir, directly into the oral mucosa. This delivery system aims to achieve high local concentrations of the antiviral agent at the site of viral replication while minimizing systemic exposure and improving patient compliance compared to multiple daily applications of topical creams. LAU-PM-05 is currently in Phase 1/2 clinical development.

Other names: penciclovir Lauriad

Targets

DNA polymerase family

Beyond the preview

Go deeper on LAU-PM-05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LAU-PM-05.

Explore the full profile